Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0MCDXO
ADC Name	LC A032D/HC
Synonyms	LC-A032D/HC Click to Show/Hide
Organization	BioAtla, Inc.
Drug Status	Investigative
Indication	In total 1 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative
	3D MOL	2D MOL
Antibody Name	BA-130-00-01		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	Undisclosed
Linker Name	LC A032D/HC linker

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 100	%	BT-474 cells	Invasive breast carcinoma
Tumor Growth Inhibition value (TGI)	≈ 100	%	BT-474 cells	Invasive breast carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 23)	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 10⁶ cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm³ mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 27)	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 10⁶ cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm³ mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

References

Ref 1	Conditionally active anti-her2 antibodies, antibody fragments their immunoconjugates and uses thereof; 2021-07-29.